

28 Aug 2022 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: Axsome gets broad label for new depression drug; Argenx CEO on Vyvgart's success; Chinese firms delist from US; solid results for Novo Nordisk's new diabetes combo; and women leaders herald change at foreign firms in India.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 26 August 2022, including: [*Axsome Therapeutics, Inc.*](#) gets broad label for new depression drug; [*argenx N.V.*](#) CEO on Vyvgart's success; Chinese firms delist from US; solid results for [*Novo Nordisk A/S*](#)'s new diabetes combo; and women leaders herald change at foreign firms in India.

This and all our other podcasts are available on the Pharma Intelligence channel on [*Apple Podcasts*](#), [*Google Podcasts*](#), [*SoundCloud*](#), [*TuneIn*](#) and [*Spotify Podcasts*](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[*Axsome's Wait Pays Off With Broad Auvelity Label For Major Depression*](#)" - Scrip, 19 Aug, 2022.)

(Also see "[*Argenx CEO Shares Secrets Of Vyvgart's Stellar Success*](#)" - Scrip, 22 Aug, 2022.)

(Also see "[*Delisting Looms As More US-Listed China Companies Seek To Move Closer Home*](#)" - Scrip, 23 Aug, 2022.)

(Also see "[*Novo Nordisk's New Diabetes Combo Shows Potential To Best Lilly's Mounjaro*](#)" - Scrip, 23

Aug, 2022.)

(Also see "[*The Old Order Changeth: Women CEOs at Foreign Firms In India Chart New Course*](#)" - Scrip, 19 Aug, 2022.)

[*Click here to explore this interactive content online*](#) 